Orange Bank Looking at Takeover Offer From Ripplewood
By Adria Calatayud
Orange Bank, the retail-banking business of French telecommunications group Orange, has received a takeover offer from U.S. investment firm Ripplewood that it is analyzing.
A spokesperson for Orange Bank said Friday that the business is studying the proposal carefully, looking in particular at the robustness of the financing plan and guarantees of job security. Financial details of the proposal weren't disclosed.
Talks with Ripplewood and employee representatives are continuing, and the offer has been presented to the bank's works council, it said.
Ripplewood couldn't immediately be reached for comment.
Orange in June said it planned to pull out of retail banking and that it had entered into exclusive negotiations with BNP Paribas, with talks focusing on Orange Bank's customer portfolio in France and the terms of a takeover of its business in Spain.
Write to Adria Calatayud at adria.calatayud@dowjones.com
(END) Dow Jones Newswires
December 22, 2023 03:36 ET (08:36 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track